Buscar
01/09/2023
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Berenguer-Ruiz S., Aparicio-Domínguez M., Herranz-Pinto P., Ruíz-Villaverde R., López-Ferrer A., Santos-Juanes J., Rodríguez Fernández-Freire L., Hospital-Gil M., Arias-Santiago S., Carretero-Hernández G., Mateu-Puchades A., Ferran M., del Alcázar E., Santos-Alarcón S., Garcia-Latasa de Aranibar F.J., Belinchón-Romero I., González-Cantero Á., Ruíz-Genao D., Eiris-Salvado N., Rocamora-Durán V., Rivera-Diaz R., de la Cueva P., Daudén E., Salgado-Boquete L., Llamas-Velasco M.. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19468. PMID:37625815. IF:8.500(Q1/1D).
01/09/2023
Epidermolysis bullosa acquisita induced by atezolizumab
Carmona-Rocha E., Aguado M., Tubau C., Sánchez S., Mozos A., Sullivan I., Spertino J.. Epidermolysis bullosa acquisita induced by atezolizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2023; DOI:10.1111/ddg.15203. PMID:37658659. IF:5.600(Q1/1D).
23/08/2023
Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
Carmona-Rocha, E, Puig, L. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy. 2023; 15(15)DOI:10.2217/imt-2023-0013. PMID:37609785. IF:2.700(Q3/7D).
23/08/2023
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)
Pereyra-Rodríguez J.J., Poveda J.L., Rivero A., Serra-Baldrich E., Silvestre J.F., Armario-Hita J.C., Calleja M.Á., Carrascosa J.M., Flórez Á., Herranz P., Comellas M., Ortiz de Frutos F.J.. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; DOI:10.1111/jdv.19432. PMID:37594914. IF:8.500(Q1/1D).